ADMA Biologics Files 8-K on Director Changes and Compensation
Ticker: ADMA · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Feb 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
Related Tickers: ADMA
TL;DR
ADMA Biologics filed an 8-K on Feb 19, 2025, covering director changes and executive pay. Check for details.
AI Summary
On February 19, 2025, ADMA Biologics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, though specific financial figures are not detailed in this summary section.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure of board and compensation changes, not indicating immediate financial distress or significant operational shifts.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant
- February 19, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 465 State Route 17, Ramsey, New Jersey 07446 (address) — Principal executive offices
- (201) 478-5552 (phone_number) — Registrant's telephone number
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific names and details of these changes are not provided in the summary information.
What are the key aspects of the compensatory arrangements mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific details of these arrangements are not elaborated upon in the provided summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 19, 2025.
What is the primary business of ADMA Biologics, Inc. according to the filing?
ADMA Biologics, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
What is the filing date of this 8-K report?
This 8-K report was filed on February 21, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding ADMA BIOLOGICS, INC. (ADMA).